FI955261A - P-selectin antibodies and their use - Google Patents

P-selectin antibodies and their use Download PDF

Info

Publication number
FI955261A
FI955261A FI955261A FI955261A FI955261A FI 955261 A FI955261 A FI 955261A FI 955261 A FI955261 A FI 955261A FI 955261 A FI955261 A FI 955261A FI 955261 A FI955261 A FI 955261A
Authority
FI
Finland
Prior art keywords
selectin antibodies
antibodies
selectin
activated
leukocytes
Prior art date
Application number
FI955261A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI955261A0 (en
Inventor
Robert W Chesnut
Margaret J Polley
James C Paulson
S Tarran Jones
Jose W Saldanha
Mary M Bendig
Michael Kriegler
Carl Perez
Robert Bayer
Michael Nunn
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1993/004274 external-priority patent/WO1993021956A1/en
Priority claimed from US08/202,047 external-priority patent/US5800815A/en
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of FI955261A0 publication Critical patent/FI955261A0/en
Publication of FI955261A publication Critical patent/FI955261A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.
FI955261A 1993-05-04 1995-11-02 P-selectin antibodies and their use FI955261A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1993/004274 WO1993021956A1 (en) 1992-05-05 1993-05-04 Antibodies to p-selectin and their uses
US5729293A 1993-05-05 1993-05-05
US08/202,047 US5800815A (en) 1903-05-05 1994-02-25 Antibodies to P-selectin and their uses
PCT/US1994/004935 WO1994025067A1 (en) 1993-05-04 1994-05-04 Antibodies to p-selectin and their uses

Publications (2)

Publication Number Publication Date
FI955261A0 FI955261A0 (en) 1995-11-02
FI955261A true FI955261A (en) 1996-01-03

Family

ID=27369213

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955261A FI955261A (en) 1993-05-04 1995-11-02 P-selectin antibodies and their use

Country Status (3)

Country Link
EP (1) EP0804235A4 (en)
FI (1) FI955261A (en)
WO (1) WO1994025067A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
WO1997000956A1 (en) * 1995-06-20 1997-01-09 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, and their uses
WO1999018442A1 (en) * 1997-10-07 1999-04-15 Centocor, Inc. Diagnosis of thrombotic events by detecting p-selectin
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
AU2012200852B2 (en) * 2004-04-13 2012-10-18 F. Hoffmann-La Roche Ag Anti-P-selectin antibodies
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
WO2008069999A2 (en) 2006-12-01 2008-06-12 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
CN101815786A (en) * 2007-10-12 2010-08-25 弗·哈夫曼-拉罗切有限公司 Protein expression from multiple nucleic acids
WO2019025847A1 (en) 2017-08-04 2019-02-07 Novartis Ag Treatment regimens
KR20210003086A (en) 2018-03-08 2021-01-11 노파르티스 아게 Use of anti-P-selectin antibodies
US20220306749A1 (en) 2019-06-07 2022-09-29 Novartis Ag Use of an Anti-P-selectin Antibody
AU2020326490A1 (en) 2019-08-08 2022-03-24 Novartis Ag Use of the anti-P-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021956A1 (en) * 1992-05-05 1993-11-11 Cytel Corporation Antibodies to p-selectin and their uses
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2097765T3 (en) * 1989-10-20 1997-04-16 New England Medical Center Inc A PADGEM INTERMEDIATED CELL LINKING INHIBITION SYSTEM.
ES2206447T3 (en) * 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.

Also Published As

Publication number Publication date
EP0804235A4 (en) 2001-09-19
EP0804235A1 (en) 1997-11-05
FI955261A0 (en) 1995-11-02
WO1994025067A1 (en) 1994-11-10

Similar Documents

Publication Publication Date Title
FI955261A (en) P-selectin antibodies and their use
ES2102196T3 (en) PERIPHERIALIZATION OF HEMATOPOYETIC PLURIPOTENTIAL CELLS.
BR9707049A (en) Anticoagulant agents usable in the treatment of thrombosis
PT833911E (en) ANTI-FACTOR ANTI-FACTOR ANTI-FACTOR CUTTED WITH CDR AND METHODS FOR THEIR USE
PT730608E (en) COMPOSITIONS COMPOSING CARBON HYDRATES AND PROEINS RELATED BY THE COMPLEMENT AND METHODS FOR PRODUCING AND USING THE COMPOSITION REFERENCES
ATE439137T1 (en) TREATMENT OF HEMATOLOGICAL DISORDERS
MX9602971A (en) Humanized antibodies against leukocyte adhesion molecule vla-4
DE122009000012I1 (en) Substituted pyrazolylbenzenesulfonamides for the treatment of inflammation.
ID29393A (en) COMPOSITION OF CANCER TREATMENT AND METHOD OF USING NATURAL PLANT ESENSIL OILS
DK0705100T3 (en) Therapeutically substituted guanidines
FI941826A (en) Methods and compositions for the prevention and / or therapeutic treatment of organ hypofunction
ATE220329T1 (en) COMPOSITION CONTAINING BRADYKININ FOR SELECTIVE OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES
DE69128543T2 (en) MONOCLONAL ANTIBODIES OF THE MOUSE
SE8605295D0 (en) MONOCLONAL ANTIBODIES CROSS-REACTIVE AND CROSSPROTECTIVE AGAINST P. AERUGINOSA SEROTYPES
DE60229406D1 (en) PROCESS FOR TREATING OR PREVENTING VASCULAR INFLAMMATION WITH STEROL ABSORBENT INHIBITOR (DE)
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
DE69405919D1 (en) Compositions for the treatment of keratin fibers
GR3018304T3 (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones.
MX9709910A (en) Inhibitors of factor xa.
ES2088128T3 (en) ACAT INHIBITOR AMINOSULFONILUREAS.
AU6633694A (en) Novel methods and compositions for the treatment of (ras)-activated cancer with heterotypic anti-(raf) antisense oligonucleotides
CA2162149A1 (en) Antibodies to p-selectin and their uses
BG100863A (en) Fibrin-specifil antibody and its use as an antithrombotic agent
GR3031095T3 (en) 3-ALKYLOXY-, ARYLOXY-, OR ARYLALKYLOXYBENZO b]THIOPHENE-2-CARBOXAMIDES AS INHIBITORS OF CELL ADHESION.
EA199800821A1 (en) METHOD OF TREATMENT OF AUTISM

Legal Events

Date Code Title Description
FD Application lapsed